Table 3.

The association between BMD response to denosumab at the femoral neck (FN) and serum PTH concentrations

	Unstandardized coefficients		Standardised coefficients	t	Sig.
	B	Standard error	Beta
Model 1
Baseline PTH (ng/L)	− 0.057	0.023	− 0.246	− 2.496	0.014
Age (years)	0.055	0.074	0.074	0.746	0.458
Model 2
Baseline PTH (ng/L)	− 0.049	0.024	− 0.212	− 2.0	0.048
Baseline eGFR (ml/min)	0.032	0.032	0.104	0.980	0.330
Model 3
Baseline PTH (ng/L)	− 0.058	0.024	− 0.252	− 2.409	0.018
Presence of secondary risk factors	0.108	1.769	0.006	0.061	0.952

Dependent variable: % change in FN BMD following treatment with denosumab

Significant values are shown in bold